Nucleocapsid S-RBD Fusion

Product Information
Primary Accession	P0DTC2 & P0DTC9
Species	SARS-CoV-2
Sequence	Full length of nucleocapsid protein and spike protein RBD region
Purity	> 75% as analyzed by SDS-PAGE
Endotoxin Level	< 0.2 EU/ µg of protein by gel clotting method
Biological Activity	SARS-CoV-2 Nucleocapsid S-RBD Fusion (His tag) can bind to both human ACE2 (Cat. No.: Z03484) and nucleocapsid antibody (Cat. No.: A02039) in functional ELISA assay.
Expression System	293 Cells
Theoretical Molecular Weight	74.9 kDa
Formulation	Supplied as a solution in PBS pH 7.4 containing 10% glycerol.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -20°C or below. Avoid repeated freeze-thaw cycles.

Additional Information
Target Background	SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. SARS-CoV-2 Spike Protein (RBD) also has the potential value for the diagnosis of the virus.